Citation: | Shenglan Zhang, Zhiran Fan, Jianfeng Liu. Generation and characterization of nanobodies targeting GPCR[J]. Biophysics Reports. doi: 10.52601/bpr.2023.230026 |
Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414(3): 521−526
|
Ayoub MA, Crepieux P, Koglin M, Parmentier M, Pin JP, Poupon A, Reiter E, Smit M, Steyaert J, Watier H, Wilkinson T (2017) Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges. mAbs 9(5): 735−741 doi: 10.1080/19420862.2017.1325052
|
Behar G, Chames P, Teulon I, Cornillon A, Alshoukr F, Roquet F, Pugniere M, Teillaud JL, Gruaz-Guyon A, Pelegrin A, Baty D (2009) Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 276(14): 3881−3893
|
Che T, Majumdar S, Zaidi SA, Ondachi P, McCorvy JD, Wang S, Mosier PD, Uprety R, Vardy E, Krumm BE, Han GW, Lee MY, Pardon E, Steyaert J, Huang XP, Strachan RT, Tribo AR, Pasternak GW, Carroll FI, Stevens RC, Cherezov V, Katritch V, Wacker D, Roth BL (2018) Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell 172(1-2): 55−67.e15 doi: 10.1016/j.cell.2017.12.011
|
Chen Y, Fleetwood O, Pérez-Conesa S, Delemotte L (2021) Allosteric effect of nanobody binding on ligand-specific active states of the β2 adrenergic receptor. J Chem Inf Model 61(12): 6024−6037 doi: 10.1021/acs.jcim.1c00826
|
De Groof TWM, Bobkov V, Heukers R, Smit MJ (2019) Nanobodies: new avenues for imaging, stabilizing and modulating GPCRs. Mol Cell Endocrinol 484: 15−24 doi: 10.1016/j.mce.2019.01.021
|
Heukers R, De Groof TWM, Smit MJ (2019) Nanobodies detecting and modulating GPCRs outside in and inside out. Curr Opin Cell Biol 57: 115−122 doi: 10.1016/j.ceb.2019.01.003
|
Hoey RJ, Eom H, Horn JR (2019) Structure and development of single domain antibodies as modules for therapeutics and diagnostics. Exp Biol Med (Maywood) 244(17): 1568−1576 doi: 10.1177/1535370219881129
|
Hutchings CJ (2020) Mini-review: antibody therapeutics targeting G protein-coupled receptors and ion channels. Antib Ther 3(4): 257−264
|
Jin BK, Odongo S, Radwanska M, Magez S (2023) Nanobodies: a review of generation, diagnostics and therapeutics. Int J Mol Sci 24(6): 5994. https://doi.org/10.3390/ijms24065994
|
Jo M, Jung ST (2016) Engineering therapeutic antibodies targeting G-protein-coupled receptors. Exp Mol Med 48: e207. https://doi.org/10.1038/emm.2015.105
|
Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 30(14): 3059−3066 doi: 10.1093/nar/gkf436
|
Liu W, Song H, Chen Q, Yu J, Xian M, Nian R, Feng D (2018) Recent advances in the selection and identification of antigen-specific nanobodies. Mol Immunol 96: 37−47 doi: 10.1016/j.molimm.2018.02.012
|
Ma Y, Ding Y, Song X, Ma X, Li X, Zhang N, Song Y, Sun Y, Shen Y, Zhong W, Hu LA, Ma Y, Zhang M-Y (2020) Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Science Advances 6(3): eaax7379. https://doi.org/10.1126/sciadv.aax7379
|
McMahon C, Staus DP, Wingler LM, Wang J, Skiba MA, Elgeti M, Hubbell WL, Rockman HA, Kruse AC, Lefkowitz RJ (2020) Synthetic nanobodies as angiotensin receptor blockers. Proc Natl Acad Sci USA 117(33): 20284−20291 doi: 10.1073/pnas.2009029117
|
Morrison C (2019) Nanobody approval gives domain antibodies a boost. Nat Rev Drug Discov 18(7): 485−487 doi: 10.1038/d41573-019-00104-w
|
Muyldermans S (2021) Applications of nanobodies. Annu Rev Anim Biosci 9: 401−421 doi: 10.1146/annurev-animal-021419-083831
|
Oh MY, Joo HY, Hur BU, Jeong YH, Cha SH (2007) Enhancing phage display of antibody fragments using gIII-amber suppression. Gene 386(1-2): 81−89 doi: 10.1016/j.gene.2006.08.009
|
Raynaud P, Gauthier C, Jugnarain V, Jean-Alphonse F, Reiter E, Bruneau G, Crépieux P (2022) Intracellular VHHs to monitor and modulate GPCR signaling. Front Endocrinol (Lausanne) 13: 1048601. https://doi.org/10.3389/fendo.2022.1048601
|
Robertson MJ, Papasergi-Scott MM, He F, Seven AB, Meyerowitz JG, Panova O, Peroto MC, Che T, Skiniotis G (2022) Structure determination of inactive-state GPCRs with a universal nanobody. Nat Struct Mol Biol 29(12): 1188−1195 doi: 10.1038/s41594-022-00859-8
|
Sheridan C (2017) Ablynx's nanobody fragments go places antibodies cannot. Nat Biotechnol 35(12): 1115−1117 doi: 10.1038/nbt1217-1115
|
Thal DM, Glukhova A, Sexton PM, Christopoulos A (2018) Structural insights into G-protein-coupled receptor allostery. Nature 559(7712): 45−53 doi: 10.1038/s41586-018-0259-z
|
Uchanski T, Pardon E, Steyaert J (2020) Nanobodies to study protein conformational states. Curr Opin Struct Biol 60: 117−123 doi: 10.1016/j.sbi.2020.01.003
|
Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF (1999) Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 112: 531−552
|
Zhang M, Gui M, Wang ZF, Gorgulla C, Yu JJ, Wu H, Sun ZJ, Klenk C, Merklinger L, Morstein L, Hagn F, Plückthun A, Brown A, Nasr ML, Wagner G (2021) Cryo-EM structure of an activated GPCR-G protein complex in lipid nanodiscs. Nat Struct Mol Biol 28(3): 258−267 doi: 10.1038/s41594-020-00554-6
|
Zimmermann I, Egloff P, Hutter CA, Arnold FM, Stohler P, Bocquet N, Hug MN, Huber S, Siegrist M, Hetemann L, Gera J, Gmur S, Spies P, Gygax D, Geertsma ER, Dawson RJ, Seeger MA (2018) Synthetic single domain antibodies for the conformational trapping of membrane proteins. Elife 7: e34317. https://doi.org/10.7554/eLife.34317
|